Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203

Authors:
  • TCThierry Conroy
    Thierry Conroy
  • FBFranck Bonnetain
    Franck Bonnetain
  • OBOlivier Bouché
    Olivier Bouché
  • OCOlivier Chapet
    Olivier Chapet
  • MCMarie-Thérèse Closon-Dejardin
    Marie-Thérèse Closon-Dejardin
  • MUMichel Untereiner
    Michel Untereiner
  • BLBernard Leduc
    Bernard Leduc
  • ÉFÉric Francois
    Éric Francois
  • JMJean Maurel
    Jean Maurel
  • JSJean-François Seitz
    Jean-François Seitz
  • BBBruno Buecher
    Bruno Buecher

Abstract
Purpose: In 1992, preoperative radiotherapy was considered in France as the standard treatment for T3-4 rectal cancers. The present randomized trial compares preoperative radiotherapy with chemoradiotherapy. Patients and Methods: Patients were eligible if they presented a resectable T3-4, Nx, M0 rectal adenocarcinoma accessible to digital rectal examination. Preoperative radiotherapy with 45 Gy in 25 fractions during 5 weeks was delivered. Concurrent chemotherapy with fluorouracil 350 mg/m2/d during 5 days, together with leucovorin, was administered during the first and fifth week in the experimental arm. Surgery was planned 3 to 10 weeks after the end of radiotherapy. All patients should receive adjuvant chemotherapy with the same fluorouracil/leucovorin regimen. The primary end point of the trial was overall survival. Results: A total of 733 patients were eligible. Grade 3 or 4 acute toxicity was more frequent with chemoradiotherapy (14.6% v 2.7%; P < .05). There was no difference in sphincter preservation. Complete sterilization of the operative specimen was more frequent with chemoradiotherapy (11.4% v 3.6%; P < .05). The 5-year incidence of local recurrence was lower with chemoradiotherapy (8.1% v 16.5%; P < .05). Overall 5-year survival in the two groups did not differ. Conclusion: Preoperative chemoradiotherapy despite a moderate increase in acute toxicity and no impact on overall survival significantly improves local control and is recommended for T3-4, N0-2, M0 adenocarcinoma of the middle and distal rectum.

This publication has 27 references indexed in Scilit: